Abstract | OBJECTIVE: METHODS: Data from 2 phase 3, randomized, placebo-controlled trials were analyzed post hoc. Treatment was administered in up to 4 treatment cycles (per cycle: 2 injections, 1-3 days apart, of CCH 0.58 mg or placebo; subsequent penile modeling) at 6-week intervals. Penile curvature was measured at baseline and after each treatment cycle (weeks 6, 12, 18, and 24). Successful response was defined as ≥20% reduction from baseline penile curvature. RESULTS: Overall, 832 men (CCH, n = 551; placebo, n = 281) were included in the analysis. After each cycle, mean cumulative percent reduction from baseline penile curvature was significantly greater with CCH vs placebo (P <.001). Following one cycle, 29.9% of CCH recipients exhibited a successful response. Among nonresponders, additional cycles of injections led to further successful responses: 60.8% of first cycle failures achieved response after fourth cycle (8 injections), 42.7% of cycle 1-2 failures achieved response after fourth cycle, and 23.5% of cycle 1-3 failures achieved response after fourth cycle. CONCLUSION: Data showed incremental benefits from each of the 4 CCH treatment cycles. Completion of a full series of 4 CCH treatment cycles may optimize improvements in penile curvature in men with PD, including among those who did not clinically respond to previous treatment cycles.
|
Authors | Matthew Ziegelmann, Yiqun Hu, Qinfang Xiang, Genzhou Liu, Michael P McLane, Landon Trost |
Journal | Urology
(Urology)
Vol. 175
Pg. 126-131
(05 2023)
ISSN: 1527-9995 [Electronic] United States |
PMID | 36863600
(Publication Type: Journal Article)
|
Copyright | Copyright © 2023 Elsevier Inc. All rights reserved. |
Chemical References |
|
Topics |
- Adult
- Aged
- Humans
- Middle Aged
- Microbial Collagenase
(administration & dosage)
- Penile Induration
(drug therapy)
- Treatment Outcome
- Randomized Controlled Trials as Topic
- Clinical Trials, Phase III as Topic
|